Er Therapeutics Stock Performance
| PNGM Stock | USD 0.0001 0.00 0.00% |
The firm owns a Beta (Systematic Risk) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and Er Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Er Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy technical and fundamental indicators, Er Therapeutics is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
Last Split Factor 3:1 | Last Split Date 2009-04-13 |
1 | Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday - Benzinga | 10/14/2024 |
2 | OLMA - Olema Pharmaceuticals, Inc. Latest Stock News Market Updates - StockTitan | 11/06/2024 |
3 | Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine - Quantisnow | 12/03/2024 |
| Total Cashflows From Investing Activities | 49 K |
PNGM |
Er Therapeutics Relative Risk vs. Return Landscape
If you would invest 0.01 in Er Therapeutics on September 26, 2024 and sell it today you would earn a total of 0.00 from holding Er Therapeutics or generate 0.0% return on investment over 90 days. Er Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than PNGM, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Er Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Er Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Er Therapeutics, and traders can use it to determine the average amount a Er Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| PNGM |
Based on monthly moving average Er Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Er Therapeutics by adding Er Therapeutics to a well-diversified portfolio.
Er Therapeutics Fundamentals Growth
PNGM Stock prices reflect investors' perceptions of the future prospects and financial health of Er Therapeutics, and Er Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PNGM Stock performance.
| Return On Asset | -0.95 | ||||
| Current Valuation | 122.36 K | ||||
| Shares Outstanding | 58.26 M | ||||
| Price To Earning | (0.06) X | ||||
| Price To Book | 143,650 X | ||||
| Net Income | (426.95 K) | ||||
| Cash And Equivalents | 650 | ||||
| Total Debt | 48.49 K | ||||
| Book Value Per Share | (0) X | ||||
| Cash Flow From Operations | (161.43 K) | ||||
| Total Asset | 423.6 K | ||||
| Current Asset | 7 K | ||||
| Current Liabilities | 645 K | ||||
About Er Therapeutics Performance
By examining Er Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Er Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Er Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Pengram Corporation, an exploration stage mining company, engages in the acquisition, exploration, and development of natural resource properties, primarily gold. Pengram Corporation was founded in 2006 and is based in Bellingham, Washington. Pengram Corp operates under Other Industrial Metals Mining classification in the United States and is traded on OTC Exchange.Things to note about Er Therapeutics performance evaluation
Checking the ongoing alerts about Er Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Er Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Er Therapeutics generated a negative expected return over the last 90 days | |
| Er Therapeutics has some characteristics of a very speculative penny stock | |
| Er Therapeutics currently holds 48.49 K in liabilities. Er Therapeutics has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Er Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (426.95 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Er Therapeutics currently holds about 650 in cash with (161.43 K) of positive cash flow from operations. | |
| Er Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine - Quantisnow |
- Analyzing Er Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Er Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Er Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Er Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Er Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Er Therapeutics' stock. These opinions can provide insight into Er Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Er Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Diversified Metals & Mining space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Er Therapeutics. If investors know PNGM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Er Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (0.95) |
The market value of Er Therapeutics is measured differently than its book value, which is the value of PNGM that is recorded on the company's balance sheet. Investors also form their own opinion of Er Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Er Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Er Therapeutics' market value can be influenced by many factors that don't directly affect Er Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Er Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Er Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Er Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.